Skip to main content
. 2015 Jan 23;17(1):124–133. doi: 10.1016/j.neo.2014.11.009

Figure 2.

Figure 2

EGFR transformed mammary epithelial cells become inherently resistant to Erlotinib following EMT-induced metastasis. (A and B) NME and NME-LM (1x106) cells were engrafted onto the mammary fat pad of female nu/nu mice and 14 days thereafter mice were treated daily with Erlotinib (50 mg/kg). At the indicated time points (line on graph), primary tumors were surgically removed and mice were monitored for recurrent tumors. (C) Bioluminescent images showing the sensitivity (NME) and resistance (NME-LM) of the indicated tumors described in panels A and B to systemic Erlotinib treatment. (D) Ex-vivo visualization and (E) weight of indicated tumors from control and Erlotinib-treated mice. (F) Pulmonary dissemination of NME-LM tumors in control and Erlotinib-treated mice was determined by bioluminescence at the indicated time points following fat pad engraftment. For panel A–B and E–F data are the mean values ± SE (n = 4 mice per group) where * indicates P < .05. (G) Representative ex vivo bioluminescence images demonstrating robust metastasis in the lungs from control and Erlotinib-treated NME-LM tumor bearing mice.